Psoriasis Drug Development Pipeline 2025​

​Release Date: Q4' 2025
Number of Candidates: 51

Synopsis: Psoriasis drugs target a chronic immune-mediated disease that requires lifelong management. Demand stays high because patients and clinicians expect deeper clearance, longer remission, and reduced systemic risk. The current psoriasis pipeline is defined by a concentrated push toward higher efficacy, longer remission, and safer long-term immune modulation. Next-generation IL-17 and IL-23 agents anchor the late-stage landscape because these pathways already deliver the strongest PASI 100 outcomes in clinical practice. Developers are refining durability, dosing intervals, and immunogenicity rather than reinventing the mechanism. TYK2 inhibitors form the most active oral segment, targeting biologic-level clearance in a pill format that can expand adoption and reduce treatment burden.
​
​Mid-stage programs explore differentiation through improved selectivity, dual-pathway targeting, and formulation innovation. Early-stage candidates include novel immunology targets, topical small molecules designed for mild-to-moderate disease, and systemic agents positioned for biologic-refractory patients. Across all stages, the pipeline reflects investor and industry confidence in psoriasis as a high-value therapeutic category with room for new entrants.

Psoriasis drugs pipeline refers to the full spectrum of investigational therapies advancing through preclinical, Phase I, Phase II, and Phase III development for the treatment of psoriasis. This pipeline is a forward-looking indicator of clinical progress, competitive pressure, and future commercial opportunity. It shows where the market is evolving and which mechanisms will dominate the next treatment era.
 Picture
Pricing:
​
Single User License: USD 1,000

Company Wide License (Single Site): USD 1,500

Company Wide License (Global Site): USD 2,500

For a Sample and Inquiries contact: [email protected]

The “Psoriasis Drugs Pipeline 2025” excel sheet presents a look at the major drug candidates currently in the clinical pipeline. 

The data-set is delivered in an Excel sheet covering clinical drug development pipeline for the psoriasis market, profiling 51 future candidates.
Picture
Pipeline Candidates Data Segmentation:
Drug pipeline data set offers a breakdown in the following subcategories:
  • Candidate (Name)
  • Developer(s)
  • Therapeutic Area(s)​
    • ​Plaque Psoriasis 
    • Psoriatic Arthritis
    • Other Psoriasis
  • Mechanism of Action(s)
    • TYK2 Inhibitor
    • TNF Inhibitors
    • EMT Protein
    • S1P Receptor
    • Interleukin Inhibitors
    • PDE4 inhibitors
    • PDT
    • JAK Inhibitors
    • VDR
    • NO Modulators
    • Others
  • Route Of Administration​
    • ​Oral
    • Topical
    • Parenteral
  • Phase
    • Pre-Clinical
    • ​Phase I
    • Phase I/II
    • Phase II
    • Phase III
    • Pre-Registration
    • Registered​​
List of Companies/Organizations Mentioned:
Acelyrin
Akeso Biopharma
Akros Pharma
Almirall
AltruBio
Alumis (Previously Esker Therapeutics)
Amgen
AnaptysBio
Aclaris Therapeutics
Artax Biopharma
BioMimetix
Bio-Thera Solutions
Boehringer Ingelheim
BMS (Bristol-Myers Squibb)
Cantargia
Can-Fite BioPharma
Celltrion
Cerbios-Pharma
Cipher Pharmaceuticals
Dermata Therapeutics
DICE Therapeutics (Acquired by Eli Lilly)
Eli Lilly and Company
Galectin Therapeutics
GSK (GlaxoSmithKline)
Immutep
Innovent Biologics
Johnson & Johnson
Janssen Biotech
Janssen Research & Development
Japan Tobacco
Lipidor
Mabpharm
Merck
MoonLake Immunotherapeutics
Ono Pharmaceutical
Pelthos Therapeutics (Part of Ligand Pharmaceuticals)
Pfizer
Photogen Technologies Inc.
Provectus Biopharmaceuticals
Rani Therapeutics
Sanofi
Suzhou Zelgen Biopharmaceuticals
Sun Pharmaceutical Industries
Takeda
UNION Therapeutics
UCB
Vanda Pharmaceuticals